CXCL17 and breast carcinoma: Moreover, preliminary immunohistochemical analyses showed that CXCL17 was positive in some clinical specimens (50% in colorectal cancer, 60% in breast cancer, and 30% in non-small cell lung carcinoma) (Figure 2C and 2D, and Figure S3B).